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100 Poster Sessions 
-~  LAMIVUDINE IS NOT EFFECTIVE IN THE TREATMENT OF 
NON-CIRRHOTIC HBeAg (-)  CHRONIC HEPATITIS B 
PATIENTS WITH LOW LEVEL VIREMIA 
Hakan Bozkaya 1 , Cihan Yurdaydin 1,Mithat Bozdayi 2, Armagan 
Kocer Sagiroglu 2, Ozlem Erkan 2, Ozden Uzunalimoglu. tAnkara 
University School of Medicine Dept. of Gastroenterology; 2Ankara 
University Institute of Hepatology, Ankara, Turkey 
Background: A subgroup of non-cirrhotic e-minus chronic hepatitis B 
(CHB) patients hows persistent ALT abnormalities despite undetectable 
HBV DNA by hybridization assays. The effect of antiviral treatment in 
these patients is not well established. Very sensitive real-time PCR assays 
may have an impact in the evaluation of the treatment inthese pts. 
Patients and Methods: 18 HBeAg (-),  HBV DNA < 5 pg/ml CHB pa- 
tients with persistently elevated ALT levels were included. Fourteen of 
them received 1 year lamivudine treatment (150 mg/qd) while remaining 
4 patients had at least 1 year of follow-up without any treatment. Four of 
14 treated patients had also more than 1 year of follow-up period before 
lamivudine treatment. Hence, we compared 14 treatment periods with 8 
control periods in a total of 18 patients. HBV DNA was measured by real- 
time PCR (100 copy/ml) at baseline and at the end of the treatment/control 
periods. 
Results: Mean baseline HBV DNA levels of treatment vs. control peri- 
ods were similar (3.9 x 104 4- 9.6 x 104 vs. 8.4 x 105 4- 2.3 x 106, 
respectively). None of the lamivudine treated but two control patients had 
>2 log decrease at the end of the treatment/control periods. Two of 14 
(14%) treated patients had ALT normalization while no change in ALT 
was observed uring 8 control periods. 
Conclusion: Lamivudine is not effective in the treatment of e-minus CHB 
patients with low level viremia. Lamivudine does not seem to further en- 
hance the immune response-mediated inhibition of viral replication in these 
patients. 
[ -~  ADEFOVIR AND PHARMACOKINETICS IN DIPIVOXlL SAFETY 
SUBJECTS WITH HEPATITIS B VIRUS INFECTION AND IN 
HEALTHY SUBJECTS 
Brian Kearney, Wanda Knight, Graeme Currie, Desiree Beutelspacher, 
Ramin Ebrahimi, Stan Gill, John Fry, Carol Brosgart. Clinical Research, 
Gilead Sciences, Foster City, California, USA 
Background: Adefovir Dipivoxil (ADV) is being evaluated for the treat- 
ment of chronic hepatitis B (HBV) infection. The safety and pharmacoki- 
netics (PK) of ADV in subjects with HBV were investigated and the effect 
of dosing with and without food was assessed. Food may alter ADV ab- 
sorption. 
Objectives: To evaluate the safety and PK of ADV in HBV patients, and 
evaluate the effect of food on ADV PK. 
Methods: Fourteen HBV subjects received once dally oral dosing of ADV 
10 mg, with PK samples measured after single and multiple doses. Eighteen 
normal subjects received 2 single doses of ADV 10 mg with and without 
a high fat meal (separated by 1 week washout), with PK measured after 
each dose. Safety was assessed via adverse vents (AEs) and laboratory 
parameters. 
Results: Fourteen HBV subjects (9 males, 5 females, mean age 40 Range: 
23-68 years) and 18 normal subjects (10 males, 8 females, mean age 29 
Range: 18-41 years) completed the studies. No serious AEs or discontin- 
uations occurred with either group. ADV was well tolerated in all sub- 
jects. ADV PK in HBV subjects were similar following single (AUC 210 
ng*hr/mL, Cmax 17.5 ng/mL) and multiple (AUC 204 ng*hr/mL, Cmax 
18.3 ng/mL) dosing Cmax and AUC in HBV patients after single and mul- 
tiple dosing were not different to those seen in healthy subjects (AUC 192 
ng*hr/mL, Cmax 20.4 ng/mL). 
Conclusion: ADV pharmacokinetics were similar in HBV and healthy 
subjects. There was no significant food effect, therefore ADV may be taken 
without regard to meals. 
-~A DRUG-DRUG INTERACTION STUDY BETWEEN ADEFOVIR 
DIPIVOXlL AND LAMIVUDINE, ACETAMINOPHEN, 
IBUPROFEN AND TRIMETHOPRIM/SULFAMETHOXAZOLE 
Brian Kearney, Wanda Knight, Graeme Currie, Jennifer Contreras, 
John Wolf, Stan Gill, John Fry, Carol Brosgart. Clinical Research, Gilead 
Sciences, Foster City, California, USA 
Background: Coadministration f adefovir dipivoxil (ADV) and lamivu- 
dine (LAM) for the treatment of HBV-infection is currently being evalu- 
ated. In Phase 3 clinical trials of ADV, the most frequently coadministered 
medications were acetaminophen (APAP), ibuprofen (IBU) and antibiotics, 
including tdmethoprim/sulfamethoxazole (TMP/SMX). It is important to 
understand the drug interaction potential of these agents with ADV, es- 
pecially as APAP can cause hepatotoxicty and IBU can result in renal 
impairment. 
Objectives: To determine whether coadministration f ADV 10 mg with 
LAM 100 mg QD, APAP 1000 mg QID, IBU 800 mg TID, or TMP/SMX 
160/800 mg BID affected the steady-state pharmacokinetics (PK) of either 
drug such that dosing modifications would be required. 
Methods: Each subject was randomized to an interaction cohort and the 
order of three treatments (ADV alone, ADV+test drug, test drug alone), 
each treatment separated by a 7-day washout. Alterations in PK (Cmax and 
AUC) were assessed using equivalence t sting (coadministered vs. dosed 
alone). 
Results: The PK of LAM, APAP, IBU, TMP/SMX were equivalent when 
dosed with ADV. There were no alterations in the PK of ADV when coad- 
ministered with these agents, except for when coadministered with IBU, 
where small increases in the Cmax (33%), AUC (23%), and urinary recov- 
ery (23%) were observed, without a change in renal clearance, suggesting 
enhanced bioavailability of adefovir. 
Condusions-" The PK of ADV and LAM, APAP, and TMP/SMX were 
unaltered by their coadministration. IBU PK was unaffected by ADV. The 
small increase in adefovir exposure when dosed with IBU is not of suffi- 
cient magnitude to necessitate a change in dose. 
~-4- I  EFFICACY OF A SHORT-SCHEDULE/HIGH DOSE HEPATITIS B 
VACCINATION IN DRUG USERS 
Suzanne Brissette 1, Marina Gomez 1, Jean Lambert 2,Bernard Willems 1. 
1 Centre Hospitalier De L'Universite De Montreal, Unite De 
Desintoxication, Montreal, Quebec; 2Centre Hospitalier De L'Universite 
De Montreal, Unite De Desintoxication, Montreal, Quebec, Canada 
Objectives: To evaluate the response rates and compliance to 4 vaccination 
programs of Hepatitis B vaccination i  drug users. 
Methods: 908 cocaine/heroin users were randomised to 4 groups (2 sched- 
ules (standard (0, 4, 24 weeks) or shorter (0, 2, 4 weeks)) and 2 doses of 
vaccine (Recombivax 10 microg or 40 microg). Response was defined as 
levels of anti-HBsAg > 10 IU/L. Compliance was determined ashaving 
received 3injections of the vaccine. 
Results: Compliance to the vaccination was better in the short schedule 
groups (73.7% vs 46.6%; p < 0.001; N = 771). Amongst these, 389 came 
back for anti-HBs measurement. Their overall response rate was 77.9%, 
lower than in the general population. The short schedule/high dose group 
developed comparable response rates to the standard schedule and dose 
group (82.4% vs 81.5%); the short schedule/standard dose had lower re- 
sponse rates (57.3%). 
Standard calendar Short calendar 
I0 microg 81.5% 57.3% 
40 microg 93.0% 82.4% 
Chi2:38.825 (p< 0.000) 
Multivariate analysis howed that he 40 microg dose was positively associ- 
ated to the response (OR: 4.731; CI 2.579-8.678) while HCV (OR: 0.300; 
CI 0.155-0.581) the short schedule (OR: 0.316; CI 0.174-0.573) and age 
